Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome.
Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome.
Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1996 - 2006
BACKGROUND: There have been concerns about the long-term safety of drug-eluting stents in the setting of acute coronary syndrome. CONCLUSIONS: There was an improvement in the long-term outcome for MACE with EES when compared to earlier-generation stents, but this was comparable with the 2nd-generation E-ZES. There was no additional risk of early or late stent thrombosis in EES when compared with BMS.Copyright � 2014 Wiley Periodicals, Inc. E-ZES: HR 1.08, 95% CI 0.65-1.77, P=0.72). Stent thrombosis rates were similar for EES, E-ZES, and BMS but higher for SES throughout the 3-year follow-up (EES vs. BMS: HR 1.02, 95% CI: 0.31-3.35, P=0.973; EES vs. SES: HR 4.90, 95% CI: 1.75-13.69, P=0.002 and EES vs. E-ZES: HR 1.63, 95% CI 0.37-7.31, P=0.449). METHODS: The study cohort included 1,612 patients presenting with acute coronary syndrome who underwent BMS, SES, E-ZES, or EES implantation. End points included probable or definite stent thrombosis and major adverse cardiovascular events (MACE), defined as a composite of all-cause death, Q-wave myocardial infarction, and target lesion revascularization up to 3 years. OBJECTIVES: This study aimed to investigate the long-term safety and efficacy of everolimus-eluting stents (EES) compared with other limus-eluting stents and bare metal stents (BMS) in ACS patients. RESULTS: The overall MACE rates were significantly higher for both BMS and SES, but not E-ZES, when compared with EES (EES vs. BMS: HR 2.68, 95% CI 1.91-3.78, P <0.001; EES vs. SES: HR 1.75, 95% CI 1.24-2.47, P=0.001 and EES vs.
English
1522-1946
*Acute Coronary Syndrome/su [Surgery]
*Coronary Restenosis/pc [Prevention & Control]
*Drug-Eluting Stents
*Percutaneous Coronary Intervention/mt [Methods]
*Sirolimus/aa [Analogs & Derivatives]
Acute Coronary Syndrome/di [Diagnosis]
Aged
Antineoplastic Agents
Cause of Death/td [Trends]
Coronary Restenosis/ep [Epidemiology]
Female
Follow-Up Studies
Humans
Immunosuppressive Agents/pd [Pharmacology]
Incidence
Male
Middle Aged
Prosthesis Design
Retrospective Studies
Risk Factors
Sirolimus/pd [Pharmacology]
Time Factors
Treatment Outcome
Washington/ep [Epidemiology]
MedStar Heart & Vascular Institute
Comparative Study
Journal Article
Available online from MWHC library: 1996 - present, Available in print through MWHC library: 1996 - 2006
BACKGROUND: There have been concerns about the long-term safety of drug-eluting stents in the setting of acute coronary syndrome. CONCLUSIONS: There was an improvement in the long-term outcome for MACE with EES when compared to earlier-generation stents, but this was comparable with the 2nd-generation E-ZES. There was no additional risk of early or late stent thrombosis in EES when compared with BMS.Copyright � 2014 Wiley Periodicals, Inc. E-ZES: HR 1.08, 95% CI 0.65-1.77, P=0.72). Stent thrombosis rates were similar for EES, E-ZES, and BMS but higher for SES throughout the 3-year follow-up (EES vs. BMS: HR 1.02, 95% CI: 0.31-3.35, P=0.973; EES vs. SES: HR 4.90, 95% CI: 1.75-13.69, P=0.002 and EES vs. E-ZES: HR 1.63, 95% CI 0.37-7.31, P=0.449). METHODS: The study cohort included 1,612 patients presenting with acute coronary syndrome who underwent BMS, SES, E-ZES, or EES implantation. End points included probable or definite stent thrombosis and major adverse cardiovascular events (MACE), defined as a composite of all-cause death, Q-wave myocardial infarction, and target lesion revascularization up to 3 years. OBJECTIVES: This study aimed to investigate the long-term safety and efficacy of everolimus-eluting stents (EES) compared with other limus-eluting stents and bare metal stents (BMS) in ACS patients. RESULTS: The overall MACE rates were significantly higher for both BMS and SES, but not E-ZES, when compared with EES (EES vs. BMS: HR 2.68, 95% CI 1.91-3.78, P <0.001; EES vs. SES: HR 1.75, 95% CI 1.24-2.47, P=0.001 and EES vs.
English
1522-1946
*Acute Coronary Syndrome/su [Surgery]
*Coronary Restenosis/pc [Prevention & Control]
*Drug-Eluting Stents
*Percutaneous Coronary Intervention/mt [Methods]
*Sirolimus/aa [Analogs & Derivatives]
Acute Coronary Syndrome/di [Diagnosis]
Aged
Antineoplastic Agents
Cause of Death/td [Trends]
Coronary Restenosis/ep [Epidemiology]
Female
Follow-Up Studies
Humans
Immunosuppressive Agents/pd [Pharmacology]
Incidence
Male
Middle Aged
Prosthesis Design
Retrospective Studies
Risk Factors
Sirolimus/pd [Pharmacology]
Time Factors
Treatment Outcome
Washington/ep [Epidemiology]
MedStar Heart & Vascular Institute
Comparative Study
Journal Article